$28.86−0.03 (−0.10%)
At close: Nov 16, 2026, 4:00 PM ET· NYSE · USD
$28.860.00 (0.00%)
After hours: Nov 16, 2026, 7:53 PM ET
Pfizer (PFE) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue is 38% below its peak, net margin 12.5%, and free cash flow (~$9.1B) tracks net income. Earnings are cash, not paper.
The four lines that matter · FY21–FY25
Revenue ($B)▼1.6%
62.6
FY21→FY25CAGR −6.3%/yr
Net income ($B)▼3.1%
7.8
one-off year: see footnoteCAGR −22.8%/yr
Free cash flow ($B)▼7.7%
9.1
FY21→FY25CAGR −25.8%/yr
Diluted EPS▼3.5%
1.36
FY21→FY25CAGR −22.9%/yr
What the receipts whisper · what a headline number hides
Share count
+0.1%
5.7bn → 5.7bn diluted shares since FY21. Broadly flat, so EPS moves with net income rather than with the share count.
Capex
$2.6B
steady at 4.2% of revenue (−9.6% YoY).
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($B)
12¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 62.1% → 74.3%. Net margin 12.5% is more than double the sector median.
The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 63,625.0 | 62,579.0 | 63,627.0 | 59,553.0 | 101,175.0 | 81,288.0 | ▼1.6% | −6.3% |
Cost of revenue | 16,940.0 | 16,067.0 | 17,851.0 | 24,954.0 | 34,344.0 | 30,821.0 | ▼10.0% | −15.0% |
Gross profit | 46,685.0 | 46,512.0 | 45,776.0 | 34,599.0 | 66,831.0 | 50,467.0 | ▲1.6% | −2.0% |
Research & development | 12,555.0 | 12,050.0 | 10,930.0 | 10,873.0 | 12,381.0 | 13,829.0 | ▲10.2% | −3.4% |
Selling, general & admin | 13,813.0 | 13,794.0 | 14,730.0 | 14,771.0 | 13,677.0 | 12,703.0 | ▼6.4% | +2.1% |
Total operating expenses | 33,045.0 | 32,268.0 | 33,365.0 | 33,320.0 | 31,042.0 | 31,034.0 | ▼3.3% | +1.0% |
Operating incomefeeds ROC rank | 13,640.0 | 14,244.0 | 12,411.0 | 1,279.0 | 35,789.0 | 19,433.0 | ▲14.8% | −7.5% |
Other income, net | −9,381.0 | −6,724.0 | −4,388.0 | −221.0 | −1,060.0 | 4,878.0 | — | — |
Pretax income | 4,259.0 | 7,520.0 | 8,023.0 | 1,058.0 | 34,729.0 | 24,311.0 | ▼6.3% | −25.4% |
Income tax | 186.0 | −266.0 | −28.0 | −1,115.0 | 3,328.0 | 1,852.0 | ▼850.0% | — |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 4,072.0 | 7,812.0 | 8,062.0 | 2,158.0 | 31,407.0 | 22,025.0 | ▼3.1% | −22.8% |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 0.70 | 1.36 | 1.41 | 0.37 | 5.47 | 3.85 | ▼3.5% | −22.9% |
Diluted shares (bn) | 5.75 | 5.71 | 5.70 | 5.71 | 5.73 | 5.71 | ▲0.2% | +0.0% |
| Margins | ||||||||
Gross margin63rd pct in Healthcare | 73.4% | 74.3% | 71.9% | 58.1% | 66.1% | 62.1% | ▲2.4pp | +12.2pp |
Operating margin | 21.4% | 22.8% | 19.5% | 2.1% | 35.4% | 23.9% | ▲3.3pp | −1.1pp |
Net margin58th pct in Healthcare | 6.4% | 12.5% | 12.7% | 3.6% | 31.0% | 27.1% | ▼0.2pp | −14.6pp |
† TTM = trailing four quarters through 2026-09-27.FY22 effective tax rate was 10% vs a −0% norm for this window, likely a one-time item; see the filing.FY23 effective tax rate was −105% vs a −0% norm for this window, likely a one-time item; see the filing.
5 more years of statements and CSV export are on Premium, and 14 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Pfizer's revenue last fiscal year?
Pfizer reported revenue of $62.6B in fiscal 2025, down 1.6% from fiscal 2024.
What was Pfizer's net income?
Pfizer reported net income of $7.8B in fiscal 2025, a net margin of 12.5%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

